DISCLAIMER

This material includes forward-looking statements based on assumptions and beliefs in light of information currently available to the Astellas and subject to significant risks and uncertainties.

This material contains information on pharmaceuticals (including compounds in research or under development) and other matters. Notwithstanding the foregoing, Astellas makes no representations, warranties, assurances or guarantees of any kind or nature whatsoever, whether expressed or implied, regarding the information in the materials (including, without limitation, no representations, warranties, assurances or guarantees as to the accuracy, sufficiency or completeness of any information, as to whether Astellas has rights to any such information or pharmaceuticals/compounds, as to whether any third party has or does not have any rights to any of such information or pharmaceuticals/compounds, as to the safety, efficacy, or effectiveness of any preparations described in this material, as to the regulatory status of or potential for regulatory agency action regarding any pharmaceuticals/compounds described in this material, or as to any uses, including unapproved uses, of any such preparations in any fashion). This material does not provide medical advice of any kind. Astellas undertakes no obligation or duty to change, remove, add, clarify, correct or update any information in the materials at any time.
EXECUTIVE SUMMARY

Preclinical and Phase 1 data:

- ASP8232 is a highly selective inhibitor of Vascular Adhesion Protein -1 (VAP-1)
- Primary indication is delaying progression of Diabetic Kidney Disease (DKD)
- ASP8232 effectively reduces albuminuria and ameliorates kidney histopathology in pre-clinical pharmacology experiments on top of ACEi/ARB treatment
- ASP8232 effectively blocks plasma VAP-1 activity in a concentration-dependent manner in rodents and humans
- ASP8232 is safe and well tolerated in healthy volunteers and in patients with renal impairment

Phase 2 data in patients with DKD:

- Treatment with ASP8232 resulted in statistically significant reduction of residual albuminuria in patients with DKD on stable ACEi/ARB treatment compared to placebo during 12 weeks treatment
- Treatment with ASP8232 was well-tolerated with an acceptable safety profile, with no SAEs related to study drug reported
ASP8232 - MECHANISM OF ACTION

- ASP8232 is a highly selective inhibitor of VAP-1.
- VAP-1 activity is implicated in multiple disorders and pathological processes that involve oxidative stress or inflammation, such as primary sclerosing cholangitis, tumour growth, graft-versus-host disease, multiple sclerosis, ischaemic brain injury, ophthalmological disorders, atherosclerosis and acute kidney injury.
- A causative role for VAP-1 in DKD has not yet been shown but is plausible because of the enzyme’s effects on oxidative stress and inflammation.
- Epidemiological studies have shown that circulating concentrations of VAP-1 are associated with albuminuria and estimated glomerular filtration rate (eGFR) in patients with diabetes and that VAP-1 independently predicts cardiovascular mortality and progression of DKD to end-stage renal failure in these patients.

De Zeeuw, D. et al., Lancet Diabetes & Endocrinol, 2018; 6: 925–33
ASP8232 - CLINICAL DEVELOPMENT

Two phase 1 studies completed

1. 8232-CL-0001: First in Man Umbrella protocol in Healthy Subjects: SAD, MAD, Food Effect, Itraconazole DDI

2. 8232-CL-0002: Phase 1b study: PK in renal impairment and exploratory safety study in Patients with DKD after 4 weeks dosing

Two Phase 2 studies completed (Proof of Concept Studies)

1. 8232-CL-0004 (ALBUM study) patients with DKD

2. 8232-CL-3001 (VIDI study) patients with DME

Astellas Clinical Trial Data Disclosure:
8232-CL-0004 (ALBUM STUDY) PATIENTS WITH DKD - STUDY DESIGN

**STUDY DESIGN**

- **1 week Screening**
- **5 weeks Pre-treatment period**
- **Randomization at Baseline**

**12 week treatment**
- ASP8232 40 mg QD
- Placebo QD

**24 weeks Follow up**

**ASP8232, capsules, 40mg**
- 1 capsule per day
- Treatment duration 12 weeks
- 1st dose taken at the site at Baseline visit
- 18 capsules per bottle

**Placebo, capsules**
- Matching ASP8232 in shape, color, taste, packaging, labeling

**Standard of Care (ACEi, ARB, anti-diabetics, antihypertensives)**

- **14 visits** over approximately 42 weeks
Primary objective:
- To evaluate the efficacy of ASP8232 in reducing Urinary Albumin to Creatinine Ratio (UACR) in subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) at 12 weeks compared to placebo.

Secondary objectives:
- To evaluate efficacy of ASP8232 in reducing the 24h urinary albumin excretion rate (AER)
- To evaluate the safety and tolerability of ASP8232
- To evaluate the pharmacokinetics (PK) of ASP8232
Inclusion

- eGFR (CKD-EPI) at screening of ≥ 25 and < 75 mL/min/1.73m²
- T2DM and anti-diabetic medication (oral and/or insulin) for ≥ 1 year prior to screening
- HbA1c level is < 11.0% (<97 mmol/mol) at screening
- Stable therapy with an ACE inhibitor or ARB for ≥ 3 months prior to screening
- Stable therapy with anti-hypertensive treatment, oral anti-diabetic agents and/or vitamin D receptor activators for ≥ 3 months prior to screening (when applicable)
- UACR is ≥ 200 and ≤ 3000 mg/g in a FMV sample at screening AND the geometric mean UACR of all FMV samples at visit 4 and at visit 5 is ≥ 200 and ≤ 3000 mg/g AND the UACR in at least 3 FMV samples at visit 4 and visit 5 is ≥ 200 mg/g

Exclusion

- Subject is on, or previously received, renal replacement therapy (e.g. dialysis or kidney transplantation).
- Renal impairment and/or albuminuria is considered to be of other origin than DKD
- Diagnosed with type 1 DM or DM with unclear etiology
- Sitting SBP<90 or >160 mmHg and/or DBP >90 mmHg at screening
<table>
<thead>
<tr>
<th></th>
<th>ASP8232 (n=60)</th>
<th>Placebo (n=60)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td>Male</td>
<td>Male</td>
</tr>
<tr>
<td></td>
<td>43 (71.7%)</td>
<td>50 (83.3%)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>Female</td>
</tr>
<tr>
<td></td>
<td>17 (28.3%)</td>
<td>10 (16.7%)</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td>69.0</td>
<td>68.5</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td>White</td>
<td>White</td>
</tr>
<tr>
<td></td>
<td>56 (93.3%)</td>
<td>57 (95.0%)</td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td>92.80</td>
<td>94.82</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>32.28</td>
<td>32.20</td>
</tr>
<tr>
<td><strong>Duration CKD (years)</strong></td>
<td>4.98</td>
<td>5.46</td>
</tr>
<tr>
<td><strong>Duration of T2DM (years)</strong></td>
<td>16.34</td>
<td>16.24</td>
</tr>
</tbody>
</table>
The primary endpoint for the study was met. For the primary analysis, 7 isolated UACR values below detection limit were excluded.

- The primary analysis performed on the mean change of log transformed UACR from baseline to EoT was statistically significant (-19.51% compared to placebo; [95% CI: -34.01, -1.82]; P = 0.033).

- The percent change from baseline in UACR was greater with ASP8232 (-17.65%; [95% CI: -28.64, -4.97]) than with placebo (2.31%; [95% CI: -11.35, 18.07]).

The secondary endpoint analysis of 24 h urinary albumin excretion was consistent with the primary endpoint.

- The placebo-adjusted reduction in albuminuria for the ASP8232 group was greater although not statistically significant (-20.00% compared to placebo; [95% CI: -38.45, 3.99]; P = 0.094).
### 8232-CL-0004 (ALBUM STUDY) PATIENTS WITH DKD - SAFETY

Most Common TEAEs Reported in ≥ 5% of Patients in Any Treatment Group (Safety Analysis Set)

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Adverse Event Preferred Term (MedDRA V 15.1)</th>
<th>ASP8232 (n=64)</th>
<th>Placebo (n=61)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal and urinary disorders</td>
<td>Renal impairment</td>
<td>9 (14.1%)</td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Edema peripheral</td>
<td>6 (9.4%)</td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Back pain</td>
<td>2 (3.1%)</td>
<td>6 (9.8%)</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Hypertension</td>
<td>2 (3.1%)</td>
<td>6 (9.8%)</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Anaemia</td>
<td>4 (6.3%)</td>
<td>0</td>
</tr>
</tbody>
</table>
Pharmacokinetics:

- ASP8232 pre-dose concentrations were steady throughout the remaining treatment period.
- The ASP8232 plasma concentrations decreased rapidly after end of treatment followed by a gradual decrease. The ASP8232 concentrations were detectable in plasma, 24 weeks after EoT.

Pharmacodynamics (VAP-1 Activity in Plasma):

- A strong and nearly complete reduction in plasma VAP-1 activity at week 2 which remained constant until week 12 (EoT) was evident following treatment with ASP8232. After week 12, VAP-1 activity increased gradually throughout the remaining treatment period, 24 weeks after EoT, to levels close to baseline.
INTELLECTUAL PROPERTY

Patent covering ASP8232

• WO2012/124696 (filed on March 13, 2012)